Foghorn Therapeutics Inc. (FHTX)

NGM – Real vaqt narxi. Valyuta: USD

4.24

-0.09 (-2.08%)

Yopilishda: May 12, 2026, 4:00 PM EDT

12.05.2026

Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May

WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the H.C.

07.05.2026

Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Lags Revenue Estimates

Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to a loss of $0.3 per share a year ago.

07.05.2026

Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update

- FHD-909 (LY4050784) Phase 1 dose-escalation trial on track; preclinical combination data with anti-PD-1 antibody demonstrates potential for robust and durable regression with anti-tumor immune memory - Selective CBP degrader FHT-171 advancing for the treatment of ER+ breast cancer with IND anticipated in 2027 -Selective EP300 degraders with potential in multiple myeloma and other hematological malignancies with IND anticipated in 2027 - Strong balance sheet with cash, cash equivalents, and marketable securities of approximately $184 million ; cash runway into the first half of 2028 WATERTOWN, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today provided a financial and corporate update in conjunction with the Company's 10-Q filing for the quarter ended March 31, 2026.

06.05.2026

Foghorn Therapeutics Inc. (FHTX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Foghorn Therapeutics (FHTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

21.04.2026

Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting

- Complete and durable regression and anti-tumor immune memory following treatment with FHD-909 (LY4050784) in combination with an anti-PD-1 antibody in preclinical syngeneic mouse models

09.04.2026

Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting

New preclinical data for FHD-909 (LY4050784) reinforcing the potential for expansion opportunities in combination with an anti-PD-1 antibody in SMARCA4 (BRG1)-mutant lung cancer

11.03.2026

Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Beats Revenue Estimates

Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to a loss of $0.3 per share a year ago.

Videolar

No Data

There is no data to display

Press-relizlar

07.05.2026

Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update

21.04.2026

Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting

- Complete and durable regression and anti-tumor immune memory following treatment with FHD-909 (LY4050784) in combination with an anti-PD-1 antibody in preclinical syngeneic mouse models

11.03.2026

Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook

FHD-909 (LY4050784) Phase 1 dose-escalation advancing as planned, targeting SMARCA4 (BRG1)-mutant cancers with a focus on non-small cell lung cancer (NSCLC)

23.02.2026

Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial Officer

WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that Ryan Maynard will join the company as Chief Financial Officer (CFO) on February 23, 2026. Mr. Maynard joins Foghorn with over 25 years of executive experience driving financial strategy, capital markets execution, and operational performance across public and private biopharmaceutical companies.

Foghorn Therapeutics Inc. (FHTX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Foghorn Therapeutics Inc. (FHTX)

Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May

Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Lags Revenue Estimates

Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update

Foghorn Therapeutics Inc. (FHTX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting

Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting

Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Beats Revenue Estimates

Videolar

No Data

Press-relizlar

Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update

Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting

Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook

Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial Officer

Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May

Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Lags Revenue Estimates

Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update

Foghorn Therapeutics Inc. (FHTX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting

Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting

Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Beats Revenue Estimates

Videolar

No Data

Press-relizlar

Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update

Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting

Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook

Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial Officer

Search stocks

Foghorn Therapeutics Inc. (FHTX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Foghorn Therapeutics Inc. (FHTX)

Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May

Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Lags Revenue Estimates

Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update

Foghorn Therapeutics Inc. (FHTX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting

Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting

Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Beats Revenue Estimates

Videolar

No Data

Press-relizlar

Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update

Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting

Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook

Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial Officer

Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May

Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Lags Revenue Estimates

Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update

Foghorn Therapeutics Inc. (FHTX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting

Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting

Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Beats Revenue Estimates

Videolar

No Data

Press-relizlar

Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update

Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting

Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook

Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial Officer